- Home
- CBAN vs ALT Comparison
CBAN vs ALT Comparison
Compare CBAN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBAN | ALT |
|---|---|---|
| Founded | 1975 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.3M | 415.3M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CBAN | ALT |
|---|---|---|
| Price | $19.33 | $3.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 164.3K | ★ 2.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | 9.68 | ★ 25.37 |
| EPS | ★ 1.17 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $35.41 | N/A |
| Revenue Next Year | $4.84 | $756,308.50 |
| P/E Ratio | $16.58 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $13.99 | $2.91 |
| 52 Week High | $21.46 | $7.73 |
Technical Indicators
Market Signals| Indicator | CBAN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 33.42 |
| Support Level | $15.96 | $3.40 |
| Resistance Level | $21.25 | $4.25 |
| Average True Range (ATR) | 0.54 | 0.24 |
| MACD | -0.14 | -0.06 |
| Stochastic Oscillator | 16.18 | 7.07 |
Price Performance
Historical ComparisonAbout CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.